ALNY
Alnylam Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$266.11
+0.61%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
31.4x
EV/EBITDA
29.2x
Market Cap
$35.61B
MomentumView details →
1D Return
+0.61%
YTD Return
−33.16%
RSI (14)
62.0
ValuationView details →
P/E (Fwd)
31.4x
EV/EBITDA
29.2x
Market Cap
$35.61B
RSI (14)
62.0
MomentumView details →
1D Return
+0.61%
YTD Return
−33.16%
SummaryUpdated Jun 1, 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a pioneering biopharmaceutical company founded in 2002 and headquartered in Cambridge, Massachusetts. The company went public in 2004 and has established itself as a leader in RNA interference (RNAi) therapeutics, a revolutionary approach to treating diseases by silencing specific genes that cause illness. Alnylam has successfully commercialized multiple RNAi-based medicines and maintains a robust pipeline targeting both rare genetic diseases and more prevalent conditions including cardiovascular, metabolic, and neurological disorders.
Similar companies
Latest newsMore news →
AstraZeneca announced on Friday that its Phase 3 clinical trial for an experimental silencer drug in ATTR-CM patients failed to show additional benefit over existing stabilizer therapy, impacting its partnership with Ionis Pharmaceuticals and the broader market.8d agoAlnylam Pharmaceuticals announced it will present new clinical and real-world data across its ATTR and hypertension programs at the ESC Congress 2026 in Munich, Germany, from August 28-31, 2026.11d ago